501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimabin vitro

  1. Haolin Liu
  2. Pengcheng Wei
  3. Qianqian Zhang
  4. Zhongzhou Chen
  5. Katja Aviszus
  6. Walter Downing
  7. Shelley Peterson
  8. Lyndon Reynoso
  9. Gregory P. Downey
  10. Stephen K. Frankel
  11. John Kappler
  12. Philippa Marrack
  13. Gongyi Zhang
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

We generated several versions of the receptor binding domain (RBD) of the Spike protein with mutations existing within newly emerging variants from South Africa and Brazil. We found that the mutant RBD with K417N, E484K, and N501Y exchanges has higher binding affinity to the human receptor compared to the wildtype RBD. This mutated version of RBD also completely abolishes the binding to a therapeutic antibody, Bamlanivimab,in vitro.

Related articles

Related articles are currently not available for this article.